Literature DB >> 15808611

Vitrification of tissue engineered pancreatic substitute.

Y C Song1, Z Z Chen, N Mukherjee, F G Lightfoot, M J Taylor, K G Brockbank, A Sambanis.   

Abstract

Despite significant advances, some critical issues remain for the long-term storage of an engineered pancreas. In this study we employed a tissue engineered pancreatic substitute model-insulin-secreting betaTC3 cells entrapped in calcium alginate/poly-L-lysine/alginate beads-to demonstrate that a prototype vitrification method can prevent ice formation and maintain cell viability/function. The results showed that the structure of the frozen samples was distorted by ice crystals throughout the matrix. In marked contrast, the vitrified samples appeared to be free of ice. Morphologic studies demonstrated extensive fractures and vacuolation in frozen specimens while there were no fractures in vitrified TEPSs. Both vitrified and frozen constructs showed some vacuolization compared to the control samples. Frozen beads showed a significantly decreased viability compared to fresh controls and the VS55 group (P < .001). There was no significant difference between the vitrified and fresh samples. Vitrification using the VS55 protocol shows similar viability and secretion properties to the control group of fresh beads. Vitrification using the PEG 400 protocol resulted in slightly lower viability and secretion properties relative to the control group; conventional freezing resulted in even significantly lower viability and secretion properties. These results combine to demonstrate feasibility of vitrification as a storage method for a tissue engineered pancreas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808611     DOI: 10.1016/j.transproceed.2004.11.027

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  9 in total

1.  Emerging technologies in medical applications of minimum volume vitrification.

Authors:  Xiaohui Zhang; Paolo N Catalano; Umut Atakan Gurkan; Imran Khimji; Utkan Demirci
Journal:  Nanomedicine (Lond)       Date:  2011-08       Impact factor: 5.307

Review 2.  Multi-scale heat and mass transfer modelling of cell and tissue cryopreservation.

Authors:  Feng Xu; Sangjun Moon; Xiaohui Zhang; Lei Shao; Young Seok Song; Utkan Demirci
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2010-02-13       Impact factor: 4.226

Review 3.  Hepatocyte cryopreservation: is it time to change the strategy?

Authors:  Xavier Stéphenne; Mustapha Najimi; Etienne M Sokal
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

4.  On-chip characterization of cryoprotective agent mixtures using an EWOD-based digital microfluidic device.

Authors:  Sinwook Park; Pavithra A L Wijethunga; Hyejin Moon; Bumsoo Han
Journal:  Lab Chip       Date:  2011-05-20       Impact factor: 6.799

5.  A method for evaluating drug penetration and absorption through isolated buccal mucosa with highly accuracy and reproducibility.

Authors:  Shuangqing Wang; Lei Liu; Saige Meng; Yuling Wang; Daofeng Liu; Zhonggao Gao; Along Zuo; Jianpeng Guo
Journal:  Drug Deliv Transl Res       Date:  2022-03-29       Impact factor: 5.671

Review 6.  Tissue engineering and regeneration of lymphatic structures.

Authors:  Evan Weitman; Daniel Cuzzone; Babak J Mehrara
Journal:  Future Oncol       Date:  2013-09       Impact factor: 3.404

7.  Cryoprotectant delivery and removal from murine insulinomas at vitrification-relevant concentrations.

Authors:  Indra Neil Mukherjee; Ying C Song; Athanassios Sambanis
Journal:  Cryobiology       Date:  2007-04-10       Impact factor: 2.487

8.  Review of vitreous islet cryopreservation: Some practical issues and their resolution.

Authors:  Michael J Taylor; Simona Baicu
Journal:  Organogenesis       Date:  2009-07       Impact factor: 2.500

9.  Development of a Vitrification Preservation Process for Bioengineered Epithelial Constructs.

Authors:  Lia H Campbell; Kelvin G M Brockbank
Journal:  Cells       Date:  2022-03-25       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.